Very common (greater than 10% of clinical trial subjects) adverse effects include diarrhea, stomatitis, rashes, dry or itchy skin, infections where finger or toenails abut skin, low platelet counts, low leukocyte counts, and low neutrophil counts. Common (between 1% and 10% of clinical trial subjects) adverse effects include interstitial lung disease.
Osimertinib
Mobocertinib
Lestaurtinib
Upadacitinib
Abrocitinib
Axitinib
Selpercatinib
Icotinib